L-Histidinol (dihydrochloride) (Standard)

[1]Kohnoe S, et al. L-histidinol potentiates hyperthermic cell-killing in-vitro. Int J Oncol. 1993 Nov;3 (5) :835-9.|[2]https://pubmed.ncbi.nlm.nih.gov/21573440/|[3]Warrington RC, et al. Effects of L-histidinol on the susceptibility of P815 mastocytoma cells to selected anticancer drugs in vitro and in DBA/2J mice. J Natl Cancer Inst. 1987 Jun;78 (6) :1177-83.|[4]Warrington RC, et al. Reversal of the multidrug-resistant phenotype of Chinese hamster ovary cells by L-histidinol. J Natl Cancer Inst. 1989 May 10;81 (10) :798-803. doi: 10.1093/jnci/81.10.798.|[5]Warrington RC, et al. L-histidinol protection against cytotoxic action of cytosine arabinoside and 5-fluorouracil in cultured mouse spleen cells. J Natl Cancer Inst. 1982 Feb;68 (2) :279-86.|[6]Zaharko D, et al. L-histidinol: preclinical therapeutic studies in combination with antitumor agents and pharmacokinetic studies in mice. Cancer Res. 1992 Jul 1;52 (13) :3604-9.|[7]Stolfi RL, et al. Chemotherapeutic activity of L-histidinol against spontaneous, autochthonous murine breast tumors. Chemotherapy. 1990;36 (6) :435-40.|[8]Badary OA, et al. Effect of L-histidinol on cisplatin nephrotoxicity in the rat. Nephron. 1997;77 (4) :435-9.|[9]Badary OA. L-Histidinol attenuates Fanconi syndrome induced by ifosfamide in rats. Exp Nephrol. 1999 Jul-Aug;7 (4) :323-7.|[10]Warrington RC, et al. L-histidinol improves the selectivity and efficacy of alkylating agents and daunomycin in mice with P388 leukaemia. Br J Cancer. 1989 Nov;60 (5) :652-6.